#United States #New York #Levi & Korsinsky #Securities Class Action #Replimune Group

Levi & Korsinsky Issues Alert to Replimune Group Investors

In a recent development, Levi & Korsinsky, LLP has alerted investors in Replimune Group, Inc. (NASDAQ: REPL) about a securities class action that has been initiated on behalf of shareholders. This alert specifically concerns those who acquired shares between October 20, 2025, and April 10, 2026. As the company faces significant challenges regarding disclosures related to its RP1 biologics license application (BLA), this case could have far-reaching implications for many investors.

Recent Stock Performance

The alert comes in the backdrop of a disastrous performance of Replimune's stock. Having peaked at $10.73 on December 8, 2025, the stock plummeted to $1.70 by April 13, 2026, marking an alarming decline of approximately 84.16%, translating to a loss of about $9.03 per share. On April 10, 2026, alone, the stock faced a severe drop of $1.15 (19.46%) to $4.76 before an extraordinary descent of $3.06 (64.29%) occurred just days later. The deadline for potential lead plaintiffs in this class action is set for October 5, 2026.

Allegations in the Class Action

At the heart of this lawsuit are serious allegations of omissions in the company's disclosures, particularly those related to its interactions with the FDA. The complaint underscores that while Replimune’s SEC filings mentioned general risks of failing to obtain FDA approval, they allegedly obscured the reality of specific deficiencies highlighted by the agency. Simultaneously, the firm is accused of failing to adequately address significant study design insights that were supposedly communicated to them during discussions with the FDA.

An alarming aspect involves the resubmission of study design data, which reportedly derived its critical response rate from a mere early unplanned analysis of 40 patients, leading to concerns about its sufficiency as it represented only 10% of the planned 400-patient enrollment. This raises critical questions about the reliability of data upon which Replimune was banking for future development.

Regulatory Concerns

Adding to the precarious stance of the company, the FDA provided a letter on April 10, 2026, stating that the studies in question do not provide sufficient evidence of effectiveness. In light of this, the complaint posits that the casual reference to risk factors in the company's communications cannot substitute for a transparent disclosure of specific operational challenges. As Joseph E. Levi, a prominent attorney representing the plaintiffs remarked, “Generic language regarding risk does not absolve a company from its obligation to provide a clear picture of the challenges and issues already known to them.”

How Affected Investors Can Respond

For affected shareholders, gathering brokerage records showing purchase dates, quantities, and prices paid becomes essential in light of the developments. While there's no immediate action required to remain a member of the class, participating involves filing necessary documentation to establish eligibility for any potential resolution thereafter.

Regardless of whether investors still hold their Replimune shares, recovery may still be possible, emphasizing that eligibility is determined by the purchase timeline rather than current ownership status. Legal representatives assure that participating in this case will generally entail no upfront costs, with fees contingent on successful recovery, thus prioritizing investor interests.

For more comprehensive details about the ongoing litigation or to check your eligibility to recover losses, contact Levi & Korsinsky, LLP, at (212) 363-7500 or via email at [email protected]. Staying informed and potentially proactive could be crucial for many clients caught in this unfolding scenario.